Piper Jaffray Maintains Rating And Price Target On Sequenom

In a report published by Piper Jaffray, Sequenom SQNM reported revenue and LPS above its, and Street, consensus expectations.

Piper Jaffray said that Sequenom generally remains on-track for the T21 assay LDT launch by the end of the year (or early 2012). “We are encouraged with the reiteration of development/commercialization time-lines. We maintain our Overweight rating and $8.50 price target on SQNM shares.”

Sequenom closed yesterday at $5.82.